Teladoc Health (TDOC) declined 0.5% following several analyst actions and earnings results. Bank of America reduced its price target from $7.50 to $7 on January 27, citing BetterHelp's monthly active users down 18.7% year-over-year in Q4, though noting flat quarter-over-quarter growth. Goldman Sachs cut its target from $9 to $8 on January 16, attributing broader MedTech and Healthcare IT stock declines to market factors rather than company fundamentals. Zacks Research decreased its FY2025 EPS estimate to negative $0.90 from negative $0.83 on February 17. The company reported full-year 2024 revenue of $2,569.6 million, down 1% year-over-year, with a net loss of $1,001.2 million. Adjusted EBITDA declined 5% for the full year and 35% in Q4. Multiple analysts maintain Hold or Neutral ratings with an average price target of $9.12.
Read full analysisTeladoc Health (TDOC) declined 0.5% following several analyst actions and earnings results. Bank of America reduced its price target from $7.50 to $7 on January 27, citing BetterHelp's monthly active users down 18.7% year-over-year in Q4, though noting flat quarter-over-quarter growth. Goldman Sachs cut its target from $9 to $8 on January 16, attributing broader MedTech and Healthcare IT stock declines to market factors rather than company fundamentals. Zacks Research decreased its FY2025 EPS estimate to negative $0.90 from negative $0.83 on February 17. The company reported full-year 2024 revenue of $2,569.6 million, down 1% year-over-year, with a net loss of $1,001.2 million. Adjusted EBITDA declined 5% for the full year and 35% in Q4. Multiple analysts maintain Hold or Neutral ratings with an average price target of $9.12.
Teladoc Health is a virtual healthcare company that connects patients with doctors via phone and video for medical consultations, mental health services, and chronic condition management. Once a pandemic-era growth darling, the stock has lost roughly a third of its value since Medicare telehealth coverage restrictions took effect January 31 and now trades below $5. A string of analyst price target cuts — from BofA, Goldman Sachs, and Citi — alongside worsening earnings estimates and declining BetterHelp engagement have created a persistent 'sell any bounce' dynamic.